Haemonetics

HAEMONETICS CORP/MASS

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Constellation Brands

News

Price Target

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

GKOS

MREO

This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Lab.People.Healthcare.thisisengineering-raeng-JzdrZzZ50tA-unsplash-copy

Long Ideas

IBRX

PGNY

Top 3 Health Care Stocks That Are Set To Fly This Quarter

Biotech

Earnings

Earnings Beats

Guidance

Health Care

General

EXAS

ISRG

Exact Sciences Corporation (NASDAQ: EXAS) reported a net loss of 9 cents per share in second-quarter 2024, narrower than the year-ago loss of 45 cents per share. The figure beat the Zacks Consensus Estimate of a loss of 37 cents per share.

Exact Sciences Q2 Loss Narrower Than Expected, Sales Beat

Haemonetics Corp

HAEMATO AG by HAEMATO AG

Press Releases

Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A

Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025

Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference

Haemonetics Announces Executive Leadership Updates

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

OBIO

Align Technology

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Cuprina Holdings (Cayman) Limited - Ordinary shares

Cuprina Holdings (Cayman)

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Technologies

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

Raymond James

Needham

JMP Securities

Barrington Research

JP Morgan

Comments

Haemonetics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell